Suven Life Sciences Limited Market Cap ($744.95 Million)
Market Cap & Net Worth: Suven Life Sciences Limited (SUVEN)
Suven Life Sciences Limited market cap. Suven Life Sciences Limited (NSE:SUVEN) has a market capitalization of $744.95 Million (Rs68.88 Billion) as of November 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #9875 globally and #498 in its home market, demonstrating a -0.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Suven Life Sciences Limited's stock price Rs261.20 by its total outstanding shares 263720583 (263.72 Million). Also see Suven Life Sciences Limited (SUVEN) cash flow conversion for how efficiently the company converts equity into cash flow.
Suven Life Sciences Limited Market Cap History (2015–2026)
Suven Life Sciences Limited market cap history from 2015 to 2026. Data shows growth from $20.96 Million to $744.95 Million (37.28% CAGR). Check Suven Life Sciences Limited share price for real-time trading data and today's change.
Suven Life Sciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Suven Life Sciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SUVEN net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.12x
Suven Life Sciences Limited's market cap is 7.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $15.12 Million | $5.00 Billion | $667.39 Million | 0.00x | 0.02x |
| 2017 | $19.92 Million | $5.44 Billion | $871.87 Million | 0.00x | 0.02x |
| 2018 | $26.05 Million | $6.13 Billion | $1.24 Billion | 0.00x | 0.02x |
| 2019 | $40.70 Million | $6.45 Billion | $869.43 Million | 0.01x | 0.05x |
| 2020 | $237.92 Million | $144.15 Million | -$942.18 Million | 1.65x | N/A |
| 2021 | $234.12 Million | $134.78 Million | -$721.51 Million | 1.74x | N/A |
| 2022 | $195.22 Million | $118.44 Million | -$1.22 Billion | 1.65x | N/A |
| 2023 | $230.30 Million | $135.39 Million | -$1.18 Billion | 1.70x | N/A |
| 2024 | $364.83 Million | $116.93 Million | -$1.05 Billion | 3.12x | N/A |
| 2025 | $474.21 Million | $66.56 Million | -$1.61 Billion | 7.12x | N/A |
Competitor Companies of SUVEN by Market Capitalization
Companies near Suven Life Sciences Limited in the global market cap rankings as of November 4, 2026. Also see Suven Life Sciences Limited assets under control for a full breakdown of the balance sheet.
Key companies related to Suven Life Sciences Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Suven Life Sciences Limited (2015–2026)
Market capitalization of Suven Life Sciences Limited from 2015 to today. Between 2015 and today, Suven Life Sciences Limited's market cap moved from $20.96 Million to $ 744.95 Million, with a yearly change of 37.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs744.95 Million | +57.09% |
| 2025 | Rs474.21 Million | +29.98% |
| 2024 | Rs364.83 Million | +58.41% |
| 2023 | Rs230.30 Million | +17.97% |
| 2022 | Rs195.22 Million | -16.62% |
| 2021 | Rs234.12 Million | -1.59% |
| 2020 | Rs237.92 Million | +484.58% |
| 2019 | Rs40.70 Million | +56.21% |
| 2018 | Rs26.05 Million | +30.83% |
| 2017 | Rs19.92 Million | +31.71% |
| 2016 | Rs15.12 Million | -27.87% |
| 2015 | Rs20.96 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Suven Life Sciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $744.95 Million USD |
| MoneyControl | $744.95 Million USD |
| MarketWatch | $744.95 Million USD |
| marketcap.company | $744.95 Million USD |
| Reuters | $744.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more